Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2022-04-29 Annual Report
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 20-F
Annual Report FY 2021
2022-04-29 English
Audit Report / Information 2021
Audit Report / Information Classification · 99% confidence The document is explicitly titled "Auditor's Report on Grifols, S.A. and Subsidiaries" and contains sections like "Independent Auditor's Report on the Consolidated Annual Accounts," "Opinion," and details about auditing procedures and Key Audit Matters. This content is characteristic of a formal audit report, which aligns with the definition for 'Audit Report / Information' (AR). Although it relates to the annual accounts (which might suggest a 10-K), the focus here is purely on the auditor's opinion and findings, making AR the most precise classification, as per the definition: 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports).' FY 2021
2022-04-29 English
Annual Report 2021
Annual Report Classification · 100% confidence The document is titled 'Cuentas anuales consolidadas 31 de diciembre 2021 y 2020' which translates to 'Consolidated Annual Accounts as of December 31, 2021 and 2020'. It contains detailed consolidated financial statements including balance sheets, income statements, cash flow statements, and statements of changes in equity. It also includes a declaration of responsibility by the board members regarding the annual financial report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. The content and structure clearly correspond to a full annual report covering the company's financial performance and position for the fiscal year. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-29 Spanish
Reformulación de las cuentas anuales consolidadas del ejercicio 2021.
Regulatory Filings Classification · 99% confidence The document is a formal communication from Grifols, S.A., dated April 28, 2022, addressed to the Comisión Nacional del Mercado de Valores (CNMV - Spanish Securities Market Commission). The content explicitly states that the company is communicating 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) regarding the reformulation (restatement) of its consolidated annual accounts for the year 2021 due to an auditor's review concerning the classification of a financial instrument related to Biomat USA. It mentions that the restated accounts have been presented electronically to the CNMV today. This is a regulatory disclosure about a significant change to previously issued financial statements, which falls under the scope of significant corporate events reported to regulators. Since it is an announcement about the restatement of annual accounts, it is not the full 10-K, nor is it a standard Earnings Release (ER). It is a specific regulatory disclosure concerning financial reporting integrity. Given the options, this type of material disclosure about financial statement adjustments, especially when filed with a regulator, is best classified as a general Regulatory Filing (RNS) or potentially related to Audit/Financial reporting. However, since it is an announcement of a material event impacting financial statements (reformulation), and not the full report itself, RNS serves as the most appropriate general regulatory disclosure category when a more specific one like 'AR' (Audit Report/Information) doesn't perfectly fit the announcement nature, or 'ER' (which is usually for initial results). Given the context of reporting material information to the regulator about restated annual accounts, RNS (Regulatory Filings) is the most suitable fallback for a specific regulatory notice that isn't a standard periodic report.
2022-04-28 Spanish
FORM 6-K
Regulatory Filings
2022-04-28 English
FORM 6-K
Regulatory Filings
2022-04-25 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.